Quantum-Si Reports Q1 Loss, Low Revenue; Highlights Key Proteus Development Milestones
QSI sits 36% above its 52-week low of $0.691.
Summary
Quantum-Si reported first-quarter 2026 financial results, including revenue of $258,000 and a net loss of $21.7 million, largely in line with anticipated poor financial performance for a development-stage company. Crucially, the company highlighted significant progress on its Proteus platform, achieving successful sequencing on integrated instruments and sequencing first customer samples. This operational advancement is vital for the company's future, as it continues to target a commercial launch of Proteus by the end of 2026, with early access sites planned for this summer. The company reiterated its full-year 2026 guidance for approximately $1.0 million in revenue, reflecting a strategic transition year focused on product readiness. With $190.4 million in cash and equivalents, Quantum-Si has sufficient runway into the second quarter of 2028 to fund its development efforts.
At the time of this announcement, QSI was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.2M. The 52-week trading range was $0.69 to $3.10. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.